Siegfried Holding AG
SFZN
Rank in Stocks
#4106
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Share Price
$88.34
Market Cap
$3.87B
Change (1 day)
1.68%
Change (1 year)
-12.97%
Country
CH
Trade Siegfried Holding AG (SFZN)
Category
Healthcare
Revenue for Siegfried Holding AG (SFZN)
Revenue in Oct 2026 TTM: 0
According to Siegfried Holding AG latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Siegfried Holding AG from 2002 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2025 | $1.67B | 16.75% |
| 2024 | $1.43B | -5.21% |
| 2023 | $1.51B | 13.69% |
| 2022 | $1.33B | 9.98% |
| 2021 | $1.21B | 28.54% |
| 2020 | $940.74M | 9.18% |
| 2019 | $861.60M | 6.71% |
| 2018 | $807.42M | 4.86% |
| 2017 | $770.00M | 9.19% |
| 2016 | $705.17M | 46.67% |
| 2015 | $480.78M | 51.48% |
| 2014 | $317.39M | -24.47% |
| 2013 | $420.19M | 4.56% |
| 2012 | $401.86M | 15.06% |
| 2011 | $349.27M | 3.82% |
| 2010 | $336.43M | 22.82% |
| 2009 | $273.92M | 1.32% |
| 2008 | $270.33M | -4.00% |
| 2007 | $281.59M | 14.52% |
| 2006 | $245.88M | 1.65% |
| 2005 | $241.89M | -14.43% |
| 2004 | $282.67M | -4.53% |
| 2003 | $296.08M | 2.63% |
| 2002 | $288.49M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
